Source
|
ENCEPHALE (n°4 vol 43 )
|
Auteur(s) :
|
CHARTIER F, Aut. ; ROUILLON Frédéric, Aut. ; BERGGREN L, Aut. ; JAMONNEAU I, Aut. ; FALISSARD Bruno, Aut. ; LLORCA Pierre-Michel, Aut.
|
Année de publication :
|
2017
|
Pages :
|
303-310
|
Notes :
|
Article en anglais
|
Mots-clés :
|
OLANZAPINE ;
ETUDE LONGITUDINALE ;
SCHIZOPHRENIE ;
|
Résumé :
|
To characterize patients treated with olanzapine pamoate in French centers and investigate the conditions of use of olanzapine pamoate in real-life treatment situation. Data came from French sites participating in an international post-authorization safety study. In this observational study, patients diagnosed with schizophrenia were receiving commercially available olanzapine pamoate, in accordance with their physician's usual standard of care. Data were collected during routine visits within the standard course of patient care [Extrait du résumé d'auteur]
|